UBS Asset Management Sells TransMedics Group Shares
UBS Asset Management Americas lowered its TransMedics Group position by 57.6% in the second quarter, after the firm sold 541,273 shares and held 398,250 shares. In parallel, UBS Group cut its TransMedics target price from $80 to $77 and kept a neutral rating, following the company’s reported $0.44 earnings per share for the quarter.